Overall, our results support further investigations on the molecular mechanisms activated by post-stroke neurorehabilitation and the role of ANG as a therapeutic target, which should be explored in vivo in pre-clinical study designs of overexpression/exogenous therapeutic administration of ANG considering the potential interaction with comorbid conditions such as diabetes, age, or hyperglycemia. The gene discussed is ANG; the disease is stroke disorder.